Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?

IF 4.3 Q1 Medicine
Uri Greenbaum , Fevzi F. Yalniz , Samer A. Srour , Katayoun Rezvani , Harjeet Singh , Amanda Olson , George Blumenschein Jr , David S. Hong , Elizabeth J. Shpall , Partow Kebriaei
{"title":"Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?","authors":"Uri Greenbaum ,&nbsp;Fevzi F. Yalniz ,&nbsp;Samer A. Srour ,&nbsp;Katayoun Rezvani ,&nbsp;Harjeet Singh ,&nbsp;Amanda Olson ,&nbsp;George Blumenschein Jr ,&nbsp;David S. Hong ,&nbsp;Elizabeth J. Shpall ,&nbsp;Partow Kebriaei","doi":"10.1016/j.bbmt.2020.06.020","DOIUrl":null,"url":null,"abstract":"<div><p>Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19<sup>+</sup> B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including (1) on-target off-tumor toxicity, (2) optimal target identification, (3) effective trafficking into bulky tumor tissue, and (4) resistance to tumor immune evasion mechanisms.</p><p>Novel techniques and modifications are being explored in both the preclinical and clinical settings, aiming to improve treatment efficacy and address the aforementioned obstacles to successful CAR T therapy in solid tumors. Here we review these challenges in a clinically oriented approach and summarize published clinical trials using CAR T therapy in a variety of solid tumors.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1759-1769"},"PeriodicalIF":4.3000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.020","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biology of Blood and Marrow Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1083879120303955","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 7

Abstract

Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19+ B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including (1) on-target off-tumor toxicity, (2) optimal target identification, (3) effective trafficking into bulky tumor tissue, and (4) resistance to tumor immune evasion mechanisms.

Novel techniques and modifications are being explored in both the preclinical and clinical settings, aiming to improve treatment efficacy and address the aforementioned obstacles to successful CAR T therapy in solid tumors. Here we review these challenges in a clinically oriented approach and summarize published clinical trials using CAR T therapy in a variety of solid tumors.

嵌合抗原受体治疗:我们如何在实体肿瘤中驱动?
免疫效应细胞(IEC)治疗是肿瘤免疫治疗领域的一种很有前途的方法。临床IEC试验主要使用嵌合抗原受体(CAR) T细胞,在CD19+ B细胞恶性肿瘤和多发性骨髓瘤中显示出良好的应答。在实体瘤中,临床前数据令人鼓舞,但临床数据尚处于起步阶段,在这种情况下使用CAR - T疗法存在挑战,包括(1)靶外肿瘤毒性,(2)最佳靶点识别,(3)有效运输到庞大的肿瘤组织,以及(4)抵抗肿瘤免疫逃避机制。新的技术和改进正在临床前和临床环境中进行探索,旨在提高治疗效果并解决上述阻碍CAR - T治疗实体瘤成功的障碍。在这里,我们以临床为导向的方法回顾了这些挑战,并总结了在各种实体瘤中使用CAR - T疗法的已发表的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
1061
审稿时长
3-6 weeks
期刊介绍: Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信